We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Fisher pricey

3 March 2020 By Neil Unmack

The $122 bln U.S. healthcare services firm is buying Qiagen for $11.5 bln. CEO Marc Casper is paying a rich price for the German diagnostics group, at a time when the coronavirus outbreak is crushing investor confidence. The timing suggests bullish spirits still linger.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)